Open AccessIncreased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry
Author(s) -
Anh Nhi Tran,
Albert Lai,
S. Li,
Whitney B. Pope,
S. Teixeira,
Robert J. Harris,
Davis C. Woodworth,
Phioanh L. Nghiemphu,
Timothy F. Cloughesy,
Benjamin M. Ellingson
Publication year - 2013
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/not198
Subject(s) - idh1 , fluid attenuated inversion recovery , isocitrate dehydrogenase , temozolomide , mutant , medicine , nuclear medicine , magnetic resonance imaging , wild type , radiation therapy , glioblastoma , cancer research , biology , radiology , enzyme , gene , biochemistry
Isocitrate dehydrogenase 1 (IDH1) mutations have been linked to favorable outcomes in patients with glioblastoma multiforme (GBM). Recent in vitro experiments suggest that IDH1 mutation sensitizes tumors to radiation damage. We hypothesized that radiographic treatment response would be significantly different between IDH1 mutant versus wild-type GBMs after radiotherapy (RT) and concurrent temozolomide (TMZ).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom